PEDIATRICS Vol. 119 No. 2 February 2007, pp. 370-380 (doi:10.1542/peds.2006-0787)
SPECIAL ARTICLE |
The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions
a Department of Pediatrics, Temple University Children's Medical Center, Temple University School of Medicine, Philadelphia, Pennsylvania
b Department of Pediatrics, Children's Hospital at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
c Division of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York
d Department of Pharmacy, Children's Hospital at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, effectively reduce coronary morbidity and mortality in high-risk adults. They are also some of the most widely prescribed medications in the United States. Their use in pediatrics, however, remains circumscribed. In this article we review the cholesterol hypothesis and focus on the knowledge base of the use of statins in adults and children. We pay particular attention to the known effects of statins in primary and secondary prevention of cardiovascular events. The toxicities of statins and their limitations in pediatrics are then considered. The use of statins in conjunction with noninvasive modalities of assessing atherosclerotic burden are also reviewed. Finally, we suggest methods to advance the use of statins in childhood that introduce their potential benefits to those individuals at highest risk for future events.
Key Words: statins pediatrics indications limitations
Abbreviations: HMG-CoA3-hydroxy-3-methyl-glutaryl coenzyme A heFHheterozygous familial hypercholesterolemia CVDcardiovascular disease LDL-Clow-density lipoprotein cholesterol FDAFood and Drug Administration CVEcardiovascular event CRPC-reactive protein BASbile-acid sequestrant EBCTelectron-beam computed tomography FMDflow-mediated dilation of the brachial artery cIMTcarotid intima-media thickness
Accepted Oct 4, 2006.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
J. N. Liberman, J. E. Berger, and M. Lewis Prevalence of Antihypertensive, Antidiabetic, and Dyslipidemic Prescription Medication Use Among Children and Adolescents Arch Pediatr Adolesc Med, April 1, 2009; 163(4): 357 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. McGill Jr, C. A. McMahan, and S. S. Gidding Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study Circulation, March 4, 2008; 117(9): 1216 - 1227. [Full Text] [PDF] |
||||
![]() |
T. B. Vaughan, F. Ovalle, and E. Moreland Vascular disease in paediatric type 2 diabetes: the state of the art Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 297 - 304. [Abstract] [PDF] |
||||







